Naratriptan Crescent Pharma (Naratriptan Hydrochloride)

Naratriptan selectively activates serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This activation causes the vessels to constrict and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and providing rapid headache relief.

The specific dose of naratriptan is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and other individual factors. Only a qualified healthcare professional should decide the appropriate dosage and frequency.

Safety data for naratriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan is a selective 5‑HT1B/1D receptor agonist, similar to other triptans such as sumatriptan and rizatriptan. Compared with some triptans, naratriptan has a longer half‑life, which may reduce the need for repeat dosing, but individual response and tolerability vary among patients.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Naratriptan Crescent Pharma is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably as soon as migraine symptoms begin. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include chest pain or tightness, hypertension, serotonin syndrome when combined with other serotonergic drugs, severe allergic reactions, cardiac arrhythmias, and rare cases of ischemic stroke. Any of these symptoms require immediate medical attention.

Naratriptan is contraindicated in patients with uncontrolled hypertension, a history of coronary artery disease, severe hepatic impairment, or known hypersensitivity to naratriptan or any excipients. It should also be avoided in individuals taking MAO inhibitors or other triptans.